Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by André Pèlegrin
Group name EquipeAP
Item Type Journal Article
Title Magnetic resonance imaging in breast cancer management in the context of neo-adjuvant chemotherapy
Creator Taourel et al.
Author P. Taourel
Author E. Pages
Author I. Millet
Author C. Bourgier
Author P. Rouanet
Author W. Jacot
Author P. Crochet
Author D. Azria
Abstract This review discusses the clinical applications of magnetic resonance imaging (MRI) for the assessment of neo-adjuvant chemotherapy (NAC) indication, axillary lymph node status, preNAC cancer prognosis, early and intermediate response to NAC, and post-NAC residual disease in patients with breast cancer. Contrast-enhanced MRI with analysis of the tumor morphological features and qualitative enhancement kinetics must be considered as the standard method for pre-NAC breast cancer staging and post-NAC residual disease assessment. Diffusion-weighted imaging (DWI) is easy to perform and may increase the specificity of breast MRI for tumor staging, and also for the assessment of tumor multifocality and multicentricity and lymph node status. It also provides an ancillary added value in the early and post-NAC response evaluation. Changes in the functional tumor volume are the main criterion for the early response analysis. Other MRI methods, such as quantitative perfusion analysis, MR spectroscopy and texture analysis, are still under study.
Publication Critical Reviews in Oncology/Hematology
Volume 132
Pages 51-65
Date Dec 2018
Journal Abbr Crit. Rev. Oncol. Hematol.
Language eng
DOI 10.1016/j.critrevonc.2018.09.012
ISSN 1879-0461
Library Catalog PubMed
Extra PMID: 30447927
Tags MRI, Neo-adjuvant chemotherapy, nonvisible, review, Revue
Date Added 2018/11/21 - 15:20:56
Date Modified 2019/12/11 - 18:36:14


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés